What is Abzena?
Abzena operates as a comprehensive partner research organization, specializing in the integrated discovery, development, and cGMP manufacture of biologics and bioconjugates. By offering a seamless suite of solutions that span from early-stage discovery to mid-phase biotherapeutic production, the firm addresses the critical bottlenecks often encountered in the biopharmaceutical pipeline. With a robust infrastructure spanning the United States and the United Kingdom, Abzena provides the technical expertise and regulatory compliance necessary to accelerate drug development timelines for its global client base. Its market position is defined by its ability to bridge the gap between laboratory-scale research and commercial-grade manufacturing, making it an indispensable partner for biotech and pharmaceutical companies alike.
How much funding has Abzena raised?
Abzena has raised a total of $113.6M across 5 funding rounds:
Stock Offering
$34.3M
Unspecified
$700K
Private Equity
$3.6M
Private Equity
$10M
Unspecified
$65M
Stock Issuance/Offering (2014): $34.3M, investors not publicly disclosed
Unspecified (2015): $700K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Private Equity (2020): $10M featuring Biospring Partners
Unspecified (2022): $65M backed by Welsh, Anderson & Stowe, and Carson
Key Investors in Abzena
Welsh, Carson, Anderson & Stowe
A leading private equity firm focused on building companies in the healthcare and technology industries through long-term strategic partnerships.
Biospring Partners
A growth-oriented investment firm that provides capital and operational support to companies at the intersection of life sciences and technology.
Undisclosed Institutional Backer
An undisclosed investor participating in the funding round to support the company's ongoing expansion and strategic development initiatives.
What's next for Abzena?
With the recent capital deployment, Abzena is well-positioned to enhance its technological infrastructure and expand its cGMP manufacturing capacity. The strategic focus will likely center on deepening its expertise in bioconjugation, a high-growth area within the therapeutic landscape. By leveraging its recent financing, the company aims to optimize its global resource allocation, ensuring that it can meet the increasing demand for integrated development services. As the biopharmaceutical sector continues to prioritize efficiency and speed-to-market, Abzena's ability to provide end-to-end solutions will be a key driver of its long-term value creation and competitive differentiation in the global market.
See full Abzena company page
